PALO ALTO, Calif.— Frazier Life Sciences (FLS), a leading investment firm focused on innovative therapeutics, has promoted Aditya Kohli, Ph.D., to Partner, the firm announced Wednesday.
Dr. Kohli joined FLS in 2016 and has since played a key role in the firm’s company creation efforts. He has co-founded six life sciences startups, including HilleVax (NASDAQ: HLVX), which went public in 2022, and Phathom Pharmaceuticals (NASDAQ: PHAT), which debuted on the public market in 2019. He also helped launch Scout Bio, which was later acquired by Ceva Santé Animale. Kohli held executive roles at both Phathom and HilleVax and currently sits on the board of HilleVax.
“Aditya has been a valued member of the FLS team, and we are thrilled to see him step into this next chapter at the firm as Partner,” said Jamie Topper, M.D., Ph.D., Managing Partner at FLS. “With over a decade of industry experience, Aditya brings strong leadership and operating expertise as we continue to build the next generation of biotech companies.”
In his new role, Kohli will maintain his focus on founding and developing early-stage biotech firms while taking on broader investment responsibilities and contributing to the firm’s overall investment strategy.
“Frazier Life Sciences is an incredibly supportive team with a long-term mindset, which makes all the difference when it comes to making thoughtful investments and providing enduring support to our portfolio companies,” said Dr. Kohli. “I’m excited to help lead our company creation efforts for innovative biotechs delivering novel therapeutics.”
Before joining FLS, Kohli was an Engagement Manager at McKinsey & Company. He earned his Ph.D. in bioengineering through a joint program between UC Berkeley and UC San Francisco and holds both B.S. and M.Eng. degrees in biological engineering from MIT.
